Cerebrolysin vs Epitalon
Both compounds have substantial research-tool positioning within the Russian/CIS neuropeptide research space, but they target very different research applications. Cerebrolysin is the multi-component porcine-brain peptide preparation with the broadest international clinical-trial evidence base for stroke, dementia, and TBI indications. Epitalon is the Khavinson pineal tetrapeptide bioregulator with the strongest long-term human follow-up data in the Khavinson short-peptide bioregulator programme, targeting longevity and cognitive-ageing research applications.
At a glance
| Cerebrolysin | Epitalon | |
|---|---|---|
| Structural class | Multi-component porcine-brain peptide preparation | Tetrapeptide bioregulator (Ala-Glu-Asp-Gly) |
| Manufacturer / origin programme | Ever Neuro Pharma (Austria) | Khavinson group (St Petersburg) |
| Primary route | Intramuscular / intravenous injection | Parenteral or oral (bioregulator formulation) |
| Approving jurisdictions | Russia, China, CIS, Central/Eastern Europe | Russia (bioregulator supplement framework) |
| UK status | No emc entry found (checked 17 October 2026) | No emc entry found (checked 17 October 2026) |
| Signature research application | Vascular dementia, acute ischaemic stroke, TBI, Alzheimer's disease research | Longevity, cognitive-ageing, telomerase-activity research |
| Evidence base | Substantial international RCT + Cochrane meta-analyses | Extended Khavinson human follow-up + preclinical body |
| Evidence tier | B | B |
Research-application positioning
Neurological injury and dementia versus longevity and cognitive-ageing
Cerebrolysin's research-application positioning is in the neurological-injury and dementia research space — post-stroke rehabilitation, traumatic brain injury recovery, vascular dementia, and Alzheimer's disease research contexts. The multi-component neurotrophic-mimicry mechanism-of-action provides pleiotropic effects on multiple pathways relevant to acute-injury recovery and chronic neurodegenerative disease.
Epitalon's research-application positioning is in the longevity and cognitive-ageing research space — extended human follow-up mortality data, telomerase-activity modulation, pineal-melatonin rhythm restoration, and biomarkers of ageing. The short-peptide-bioregulator mechanism-of-action targets systemic ageing biology rather than acute neurological injury per se.
For research designs the two positioning angles are complementary rather than substitutable. Cerebrolysin is well-suited to acute-injury and dementia-progression research questions; Epitalon is well-suited to cognitive-ageing and healthspan research questions where the long-timeframe biological substrate is more important than acute neurological effect.
Evidence-base architecture
Broad international RCT programme versus concentrated single-lab long-follow-up
Cerebrolysin's evidence-base architecture is broad and international — multi-country RCTs across multiple indications with Cochrane systematic-review coverage. The methodology is mixed, and the Cochrane conclusions are that evidence is insufficient to support Western licensed use, but the breadth of the evidence-base is substantially greater than for any other compound in the Russian/CIS multi-component neuropeptide-preparation family.
Epitalon's evidence-base architecture is concentrated but temporally distinctive — the extended Khavinson human follow-up study is one of the longest-running peptide-bioregulator human-outcome studies available, with reported effects on all-cause mortality and biomarkers of ageing across 10+ year follow-up windows. The evidence is concentrated in the single Khavinson research programme rather than replicated across international research groups.
Each evidence-base has distinct methodological limitations. Cerebrolysin's breadth-limited methodological quality means individual trial quality is variable. Epitalon's concentration in a single research programme means independent replication is limited. Neither compound meets Western regulatory-science standards for licensed cognitive-indication use.